RxDoctor Payments DataLook up a doctor →

Caroline Mbogua, MD

Internal Medicine · Houston, TXNPI 1942221148

Payments from drug & device makers

$5,951,798in general payments, 2019–2025

Across 1,275 payments — averaging $4668.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3.2M
  • Evofem Biosciences, Inc.$451K
  • GSK$442K
  • Endo Pharmaceuticals Inc.$310K
  • Regeneron$274K
  • Novo Nordisk AS$248K
  • plus $979K from 27 others
$125,384in research payments, 2019–2025

Across 14 payments — averaging $8956.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Motive Health, Inc.$101K
  • Bausch Health US, LLC$23K
  • AbbVie$699
  • GSK$583

What the payments were for

  • Travel & lodging$2,34755%
  • Food & beverage$1,89845%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,951,798 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$102,641
Medicare patients
146
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$59,903
TradjentaLinagliptin99$25,963
GlatopaGlatiramer Acetate12$23,814
XifaxanRifaximin17$23,598
XareltoRivaroxaban32$11,915
TrulicityDulaglutide11$11,058
RybelsusSemaglutide14$10,328
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,996
RexultiBrexpiprazole11$8,079
TrulancePlecanatide21$5,852
JardianceEmpagliflozin16$5,674
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$5,222
JanuviaSitagliptin Phosphate15$5,169
Budesonide29$5,060
Lurasidone Hcl13$4,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28,898$59,903190 claims
Boehringer IngelheimTradjenta, Jardiance$8,250$31,637115 claims
Johnson & JohnsonXarelto$50$11,91532 claims
GSKTrelegy Ellipta$442,262$8,99615 claims
Otsuka America Pharmaceutical, Inc.Rexulti$235$8,07911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →